GlassScriptPhysician profile
Bicheng Nan
NPI 1679768089
$2,957.46
in general payments reported to CMS, 2019-2025
18 companies · $89.50 in 2025
The $89.50 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $517 · 2020: $176 · 2021: $694 · 2022: $658 · 2023: $405 · 2024: $418 · 2025: $89.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $849 · Education: $63.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $848.74 |
| Education | $63.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $836.32 | 2021-2025 | |
| Vifor Pharma, INC. | $531.35 | 2019-2024 | Veltassa |
| Astrazeneca Pharmaceuticals LP | $375.70 | 2019-2025 | Farxiga, Lokelma |
| Amgen INC. | $282.19 | 2020-2023 | Prolia, Evenity |
| Horizon Therapeutics Plc | $154.45 | 2022 | |
| Melinta Therapeutics, LLC | $113.68 | 2019 | |
| Pfizer INC. | $111.17 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.04 | 2023-2024 | Jardiance |
| Fresenius USA Marketing, INC. | $92.58 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $82.91 | 2019 | |
| Mallinckrodt Hospital Products INC. | $74.77 | 2023 | Terlivaz |
| Otsuka America Pharmaceutical, INC. | $48.98 | 2021 | |
| Alexion Pharmaceuticals, INC. | $40.50 | 2022 | |
| Calliditas Therapeutics US INC. | $35.78 | 2023-2024 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $27.80 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| E.R. Squibb & Sons, L.L.C. | $17.61 | 2021 | |
| Travere Therapeutics, INC. | $9.02 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bicheng Nan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.